SNX-5422 has been granted Orphan Drug Status for neuroendocrine tumors by the FDA
SNX-5422 is an orally active Hsp90 inhibitor that has provided durable clinical responses in open label trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors
